Resum
Manidipine is a lipophilic, third-generation, highly vasoselective, dihydropyridine (DHP) calcium channel antagonist, which, when given on a once-daily basis, effectively reduces blood pressure (BP) in patients with mild-to-moderate essential hypertension. Manidipine has a gradual onset and a long duration of action, effectively maintaining reduced BP levels throughout the 24-hour dosing period, and is effective in the long term with no evidence of intolerance. The BP-lowering capacity of manidipine is similar to that of other established DHPs and of angiotensin-converting enzyme inhibitors. Diabetic patients and very elderly patients with mild-to-moderate hypertension also respond favourably to treatment with manidipine. Manidipine has neutral effects on glucose and lipid metabolism and is generally well tolerated. Manidipine thus represents a first-line option for lowering BP in patients with mild-to-moderate hypertension. © 2005 Adis Data Information BV. All rights reserved.
| Idioma original | Anglès |
|---|---|
| Pàgines (de-a) | 11-19 |
| Revista | Drugs |
| Volum | 65 |
| Número | SUPPL. 2 |
| Estat de la publicació | Publicada - 27 d’oct. 2005 |
SDG de les Nacions Unides
Aquest resultat contribueix als següents objectius de desenvolupament sostenible.
-
ODG 3 – Bona salut i benestar
Fingerprint
Navegar pels temes de recerca de 'Antihypertensive effect of manidipine'. Junts formen un fingerprint únic.Com citar-ho
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver